Vera Therapeutics, Inc. Class A Common Stock Earnings Dividend
Earnings Summary
Revenue | $0Mn |
Net Profits | $-109.47Mn |
Net Profit Margins | -Inf% |
Vera Therapeutics, Inc. Class A Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Vera Therapeutics, Inc. Class A Common Stock has generated NaN% jump in its revenue since last 3-months.
Vera Therapeutics, Inc. Class A Common Stock’s net profit fell -43.04% since last year same period to $-109.47Mn in the Q2 2026. On a quarterly growth basis, Vera Therapeutics, Inc. Class A Common Stock has generated 9.55% jump in its net profits since last 3-months.
Vera Therapeutics, Inc. Class A Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Vera Therapeutics, Inc. Class A Common Stock has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -1.72 |
EPS Estimate Current Year | -1.72 |
Vera Therapeutics, Inc. Class A Common Stock’s earning per share (EPS) estimates for the current quarter stand at -1.72 - a -7.5% fall from last quarter’s estimates.
Vera Therapeutics, Inc. Class A Common Stock’s earning per share (EPS) estimates for the current year stand at -1.72.
Key Ratios
Earning Per Share (EPS) | -1.52 |
Vera Therapeutics, Inc. Class A Common Stock’s earning per share (EPS) fell -26.67% since last year same period to -1.52 in the Q2 2026. This indicates that the Vera Therapeutics, Inc. Class A Common Stock has generated -26.67% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-08-10 | -1.6 | -1.52 | 5% |
2026-05-07 | -1.37 | -1.69 | -23.36% |
